

La Renon

For Across the Spectrum of NVAF Patients

# Apixagress

Apixaban 2.5 Mg & 5 Mg Tablets

With

Proven Efficacy  
& Less Bleeding  
Risk!!



For Across the Spectrum of **NVAF Patients**

# Apixagress

Apixaban 2.5 Mg & 5 Mg Tablets

## Description :

Apixagress is available as film coated tablet of Apixaban, in two strengths i.e 2.5 mg & 5 mg.

## Indication :

- ◆ Reduce the risk of stroke and systemic embolism resulting from nonvalvular atrial fibrillation.
- ◆ For the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE).
- ◆ For the treatment of DVT and PE and the reduction in risk of DVT and PE following initial therapy.

## Mechanism of Action :

Apixaban is an orally available Factor Xa antagonist.

- ◆ Apixaban inhibits free and clot-bound FXa, and prothrombinase activity.
- ◆ Apixaban has no direct effect on platelet aggregation.
- ◆ By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.

## Dosage and Administration :

Prophylaxis of DVT: The recommended dose is 2.5 mg orally twice daily.

Patients with NVAF: The recommended dose is 5 mg orally twice daily.

Treatment of DVT & PE: The recommended dose is 10 mg orally twice daily.

## Presentation :

Apixagress is available as 10 tablets in a strip.

DVT: Deep vein thrombosis, PE : Pulmonary Embolism, NVAF : Nonvalvular atrial fibrillation.

Reference: © Hospital Practice, Volume 39, Issue 4, October 2011, ISSN – 2154-8331

### La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,  
S.G. Highway, Ahmedabad-380015, Gujarat, India.

Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998

E-mail: info@larenon.com | Web: www.larenon.com

am: \_\_\_\_\_  
Call me on: \_\_\_\_\_  
Mail me at: \_\_\_\_\_

©2022 All rights reserved, La Renon Healthcare Private Limited